Quantcast

Latest MicroRNA Stories

2014-02-05 08:29:18

-Regulus to Develop microRNA-21 for Alport Syndrome, a Life-Threatening Orphan Kidney Disease, and microRNA-21 in Oncology, to Human Proof-of-Concept- LA JOLLA, Calif., Feb. 5, 2014 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ:RGLS) announced today that it has renewed its strategic alliance with Sanofi to discover, develop, and commercialize microRNA therapeutics to focus on specific orphan disease and oncology targets. Regulus will lead development of its fibrosis...

2014-02-03 16:25:26

LA JOLLA, Calif., Feb. 3, 2014 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced that Kleanthis G. Xanthopoulos, Ph.D., President and CEO of Regulus, will present a company overview at the 16(th) Annual BIO CEO & Investor Conference being held at the Waldorf-Astoria Hotel in New York City on Tuesday, February 11, 2014 at 11:30 am EST. Dr....

2014-01-22 12:12:34

Researchers have identified diagnostic microRNA panels in whole blood that had the ability to distinguish, to some degree, patients with and without pancreatic cancer, according to a study in the January 22/29 issue of JAMA. The authors caution that the findings are preliminary, and that further research is necessary to understand whether these microRNAs have clinical implications as a screening test for early detection of pancreatic cancer. MicroRNAs regulate gene expression and play...

2014-01-13 16:26:15

GENSIGNIA plans to introduce minimally invasive diagnostic test which is urgently needed to improve the diagnostic performance of high resolution imaging for lung cancer detection LONDON, MILAN, and SAN DIEGO, Jan. 13, 2014 /PRNewswire/ -- GENSIGNIA Ltd, a London-based, privately held molecular diagnostics company with laboratory operations in San Diego, CA, and Fondazione IRCCS, Istituto Nazionale dei Tumori (INT), Milan, a National Cancer Research Center in Italy, announced...

2014-01-13 08:27:16

-Regulus microMarkers(TM) Designed to Support Regulus' Therapeutic Pipeline, its Collaborators and Strategic Partners- LA JOLLA, Calif., Jan. 13, 2014 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, announced today that it has established Regulus microMarkers(TM), a new research and development division of Regulus designed to support the expansion of its innovative...

2014-01-09 08:27:30

HOERSHOLM, Denmark and SAN DIEGO, Jan. 9, 2014 /PRNewswire/ -- Santaris Pharma A/S, a privately held biopharmaceutical company, announced today that they have signed a worldwide strategic alliance with Roche to discover and develop novel RNA targeted medicines using Santaris Pharma's proprietary Locked Nucleic Acid (LNA) Drug Platform. (Logo: http://photos.prnewswire.com/prnh/20100111/SPLOGO) Under the terms of the agreement, Santaris Pharma and Roche will collaborate on the...

2014-01-08 12:29:45

LONDON, Jan. 8, 2014 /PRNewswire/ -- Reportbuyer.com just published a new market research report: Global Analysis of MicroRNA Tools and Services Market Evolving microRNA Market Provides an Opportunity for Vendors of qRT-PCR and Functional ToolsThe study covers the analysis and forecasts of MicroRNA tools and services market globally for the period 2009 to 2017. The market is broadly classified into 2 major segments - tools and services. MicroRNA tools market is further segmented...

2014-01-08 08:28:05

HOERSHOLM, Denmark, SAN DIEGO, and MUNICH, Jan. 8, 2014 /PRNewswire/ -- Santaris Pharma A/S and BetaIsarna Therapeutics GmbH announced today that they have signed an agreement whereby Isarna gains access to Santaris' Locked Nucleic Acid (LNA) technology to further develop its next generation oligonucleotide product candidates. Under the terms of the agreement, Isarna obtains rights to utilize Santaris Pharma's proprietary LNA Drug Platform to discover, develop and commercialize...

2014-01-07 16:25:27

LA JOLLA, Calif., Jan. 7, 2014 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ: RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced that Kleanthis G. Xanthopoulos, Ph.D., President and Chief Executive Officer of Regulus, will present a company overview at the 32nd Annual J.P. Morgan Healthcare Conference on Thursday, January 16, 2014 at 8:30 AM PST at the Westin St. Francis Hotel in San Francisco, CA....

2014-01-06 12:24:30

Studies Show New Methods for Early Diagnosis of Breast Cancer and Prediction of Its Spread in Women's Health Issue of Clinical Chemistry WASHINGTON, Jan. 6, 2014 /PRNewswire-USNewswire/ -- Two new papers in the "Advancing Women's Health" issue of Clinical Chemistry, the journal of AACC, show for the first time that measuring the amount of certain protein fragments and microRNAs in a woman's blood and breast tissue might enable the early diagnosis of breast cancer or prediction of its...


Word of the Day
barghest
  • A goblin in English folklore, often appearing in the shape of a large dog and believed to portend imminent death or misfortune.
  • A ghost, wraith, hobgoblin, elf, or spirit.
The origin of 'barghest' is not known, but it may be from perhaps burh-ghest, town-ghost, or German Berg-geist (mountain spirit) or Bär-geist (bear-spirit).
Related